Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[31] Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
John Tesser
Iris Lin
Natalie J. Shiff
Soumya D. Chakravarty
Gabriela Schmajuk
Nevin Hammam
Sheetal Desai
Clinical Rheumatology, 2022, 41 : 2319 - 2327
[32] Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
Broadwell, Aaron
Schechtman, Joy
Conaway, Douglas
Kivitz, Alan
Shiff, Natalie J.
Black, Shawn
Xu, Stephen
Langholff, Wayne
Schwartzman, Sergio
Curtis, Jeffrey R.
BMC RHEUMATOLOGY, 2023, 7 (01)
[33] Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
Aaron Broadwell
Joy Schechtman
Douglas Conaway
Alan Kivitz
Natalie J. Shiff
Shawn Black
Stephen Xu
Wayne Langholff
Sergio Schwartzman
Jeffrey R. Curtis
BMC Rheumatology, 7
[34] INTEGRATED SAFETY DATA ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
Husni, M. E.
Schwartzman, S.
Deodhar, A.
Kafka, S.
Chakravarty, S. D.
Hsia, E. C.
Harrison, D. D.
Leu, J. H.
Zhou, Y.
Lo, K. H.
Kavanaugh, A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 608 - 609
[35] Golimumab: a guide to its use in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Drugs & Therapy Perspectives, 2010, 26 (4) : 1 - 4
[36] INTRAVENOUS IRON IN RHEUMATOID ARTHRITIS
CLARK, AM
LANCET, 1949, 257 (NOV5): : 860 - 861
[37] A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Weinblatt, Michael E.
McInnes, Iain B.
Kremer, Joel M.
Miranda, Pedro
Vencovsky, Jiri
Guo, Xiang
White, Wendy I.
Ryan, Patricia C.
Godwood, Alex
Albulescu, Marius
Close, David
Burmester, Gerd R.
ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 49 - 59
[38] Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
Kanbe, Katsuaki
Chiba, Junji
Inoue, Yasuo
Taguchi, Masashi
Yabuki, Akiko
CLINICAL MEDICINE INSIGHTS-ARTHRITIS AND MUSCULOSKELETAL DISORDERS, 2015, 8 : 25 - 32
[39] Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Kay, Jonathan
Matteson, Eric L.
Dasgupta, Bhaskar
Nash, Peter
Durez, Patrick
Hall, Stephen
Hsia, Elizabeth C.
Han, John
Wagner, Carrie
Xu, Zhenhua
Visvanathan, Sudha
Rahman, Mahboob U.
ARTHRITIS AND RHEUMATISM, 2008, 58 (04): : 964 - 975
[40] Clinical Efficacy and Adverse Effects of Golimumab in the Treatment of Rheumatoid Arthritis
Chovel-Sella, Aluma
Karplus, Rebekah
Sella, Tal
Amital, Howard
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2012, 14 (06): : 390 - 394

← 1 2 3 4 5 →